BA
TVTX icon

Boston Advisors’s Travere Therapeutics TVTX Stock Holding History

Boston Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-79,947
Closed -$2.3M – 671
2018
Q3 		$2.3M Sell
79,947
-119,337
-60% -$3.41M 0.1% 260
2018
Q2 		$5.43M Buy
199,284
+58,727
+42% +$1.56M 0.14% 162
2018
Q1 		$3.14M Sell
140,557
-62,453
-31% -$1.49M 0.08% 237
2017
Q4 		$4.28M Sell
203,010
-5,880
-3% -$134K 0.09% 235
2017
Q3 		$5.2M Sell
208,890
-10,275
-5% -$226K 0.12% 206
2017
Q2 		$4.25M Sell
219,165
-10,840
-5% -$197K 0.1% 228
2017
Q1 		$4.25M Buy
230,005
+45,050
+24% +$881K 0.1% 233
2016
Q4 		$3.5M Sell
184,955
-33,370
-15% -$682K 0.08% 259
2016
Q3 		$4.89M Buy
218,325
+191,380
+710% +$3.64M 0.12% 204
2016
Q2 		$480K Buy
26,945
+5,185
+24% +$83.9K 0.01% 492
2016
Q1 		$297K Sell
21,760
-420
-2% -$6.37K 0.01% 589
2015
Q4 		$428K Buy
+22,180
New +$443K 0.01% 499

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boston Advisors's TVTX Position: Q4 2018 in Review

Boston Advisors sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 79,947 shares — an estimated $2.3M sold.

Boston Advisors first reported a position in TVTX in Q4 2015 and held it in 12 quarters. The position peaked at $5.43M in Q2 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • Boston Advisors reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Boston Advisors sold 79,947 Travere Therapeutics shares in Q4 2018, an estimated $2.3M.
  • Boston Advisors first reported a position in Travere Therapeutics in Q4 2015 and held it in 12 quarters.
  • Boston Advisors's Travere Therapeutics position peaked at $5.43M in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on Boston Advisors's 13F filing for Q4 2018, filed 16 Jan 2019.